Obesity and Type 2 diabetes mellitus are associated with abnormal regulation of glucocorticoid metabolism that are highlighted by clinical similarities between the sequelae of insulin resistance and Cushing's syndrome, as well as glucocorticoids' functional antagonism to insulin. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activates functionally inert glucocorticoid precursors (cortisone) to active glucocorticoids (cortisol) within insulin target tissues, such as adipose tissue, thereby regulating local glucocorticoid action. Recent data, mainly from rodents, provide considerable evidence for a causal role of 11β-HSD1 for the development of visceral obesity and Type 2 diabetes though data in humans are not unequivocal. This review summarizes current evidence on a possible role of 11β-HSD1 for development of the metabolic syndrome, raising the possibility of novel therapeutic options for the treatment of Type 2 diabetes by inhibition or down-regulation of 11β-HSD1 activity.
by increased waist-to-hip ratio-rather than lowerbody (gynoid) obesity is associated with glucose intolerance and other features of the metabolic syndrome, and represents an important predictor for increased morbidity and mortality, not only from diabetes but also from coronary heart disease and certain cancers [4] . Although the WHR encompasses both intra-abdominal (visceral) and abdominal subcutaneous adipose depots, more detailed studies emphasize the importance of the visceral component for the development of metabolic disorders [4] . A causal relationship of visceral obesity for insulin resistance was recently demonstrated by surgical removal of visceral (epididymal and perinephric) fat pads of obese Sprague-Dawley rats that markedly improved hepatic insulin sensitivity and reduced hepatic glucose production [5] .
A number of theories have been introduced to explain the close association of Type 2 diabetes mellitus and visceral obesity. Beyond genetic factors determining fat distribution and overeating as a common cause for both obesity and Type 2 diabetes, direct venous Obesity has become an epidemic in the western world and is tightly associated with Type 2 diabetes mellitus and other manifestations of the metabolic syndrome [1, 2] . The metabolic syndrome comprises a variety of disorders including Type 2 diabetes and hyperlipidaemia that relate to a loss of insulin sensitivity in important target tissues such as adipose tissue, muscle and liver [1, 3] . Upper-body (android) obesity-measured drainage of visceral adipose tissue to the liver and distinct regional differences of adipocyte biology could play an important role for the development of the metabolic syndrome [4] . One distinctive feature of visceral adipose tissue is its particular responsiveness to glucocorticoids. Not only do visceral adipocytes express higher numbers of glucocorticoid receptors [6] , also the local interconversion of inactive glucocorticoid precursors into active glucocorticoids appears considerably more pronounced in visceral than in subcutaneous adipose tissue [7] . This reaction is catalyzed by the 11β-hydroxysteroid dehydrogenase Type 1 (11β-HSD1), which converts cortisone to cortisol. Thus, the association of visceral adipose tissue and insulin resistance could be provoked by regionally altered steroid responsiveness with 11β-HSD1 playing a central role.
Insulin antagonism of glucocorticoids
Glucocorticoids are functional antagonists of insulin action. They impair insulin-dependent glucose uptake and increase lipolysis, enhance hepatic gluconeogenesis and provide substrates by promoting proteolysis [8] , and directly inhibit insulin secretion from pancreatic beta cells [9, 10, 11] . Whereas insulin inhibits hepatic gluconeogenesis, glucocorticoids enhance glucose production in the liver both directly by transactivating crucial genes involved in this process and indirectly by stimulation of other hormones, e.g. glucagon. Hepatic expression of the gene for phosphoenolpyruvate carboxykinase (PEPCK), the enzyme catalyzing the rate-limiting step in gluconeogenesis is regulated by a strong glucocorticoid response unit and is also responsive to the cAMP regulatory element binding protein (CREB) [12] . Glucocorticoids and CREB synergistically induce peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1), a key activator of hepatic gluconeogenesis [13, 14] . In addition, glucocorticoids oppose other metabolic insulin actions including insulin signalling and inhibit insulin-stimulated glucose uptake by inhibiting the translocation of the glucose transporter GLUT4 to the plasma membrane [15] .
Opposing effects of glucocorticoids to insulin action are also evident in clinical situations. Patients with Cushing's syndrome have a lower maximal glucose disposal rate during hyperinsulinaemic clamp studies compared to control subjects. Insulin-dose-response curves are shifted to the right in patients with Cushing's syndrome disclosing insulin resistance [16] and up to 20% develop impaired glucose tolerance or frank diabetes. Moreover, treatment with glucocorticoids decreases insulin sensitivity and exacerbates hyperglycaemia in diabetic patients [17] . On the other hand, insulin opposes glucocorticoid action as shown by the fact that increased insulin sensitivity during intensive treatment for Type 2 diabetes decreases glucocorticoid receptor expression in skeletal muscle [18] . Thus, decreased insulin sensitivity could release glucocorticoid sensitivity from insulin-mediated inhibition and favour a downward spiral of insulin sensitivity along with increasing glucocorticoid responsiveness.
In addition to the functional antagonism of insulin and glucocorticoids, there are striking clinical similarities between Cushing's syndrome and the metabolic syndrome X that point to a common underlying mechanism [11] . Besides insulin resistance, both syndromes share hypertension, visceral obesity, hyperlipidaemia and glucose intolerance up to overt diabetes mellitus. However, circulating glucocorticoid concentrations are commonly not increased in obesity or Type 2 diabetes.
11β-HSD1: expression and function
Prereceptor regulation of glucocorticoid action. The main determinants of steroid action were formerly thought to be their plasma concentrations, the extent of binding to plasma proteins and the density of their receptors in target tissues. In addition, enzymes modifying hormone chemistry in target tissues exist for a variety of hormones that bind to nuclear receptors, e.g. 5α-reductase for the androgen and 5′-monoiodinases for thyroid hormones [19] . These prereceptor pathways potently modulate the local hormone concentration and action. For glucocorticoids, chemical residues at the 11-position, either 11β-hydroxy or 11-oxo moieties, determine whether or not steroids are able to bind to glucocorticoid (and mineralocorticoid) receptors. Glucocorticoid receptor binding is restricted to steroids with 11β-hydroxyl moieties, i.e. mainly cortisol in humans and corticosterone in rodents, respectively. The responsible proteins, the 11β-hydroxysteroid dehydrogenases (11β-HSD), exist in two isoforms with only 21% identity [20] (Fig. 1 ). 11β-HSD type 2 is predominantly expressed in kidney and catalyses the 11β-dehydrogenase reaction that rapidly inactivates active glucocorticoids (cortisol, corticosterone) by converting to cortisone or 11-dehydro-corticosterone, respectively, to ensure selectivity of the mineralocorticoid receptor. On the other hand, 11β-HSD1 activates inert precursors (cortisone, 11-dehydro corticosterone) to active glucocorticoids by oxoreductase activity in liver, adipose tissue, brain, skeletal muscle, vascular smooth muscle cells and other organs [21] . Though 11β-HSD1 appears to act as an oxo-reductase in most if not all instances, recent reports suggest the possibility of a switch to the 11β-dehydrogenase reaction by the same enzyme with the direction of the reaction being regulated, e.g., by the state of cellular differentiation and endoplasmic redox potential, as discussed below. For readers' convenience, this review consistently refers to the glucocorticoid-activating oxo-reductase reaction when speaking of 11β-HSD1 activity.
During diurnal nadir, only approximately 5% of cortisol circulates unbound in a thermodynamically "free" form to access glucocorticoid receptors, whereas most cortisol is bound to corticosteroid-binding globulin or albumin in blood plasma. Since these binding proteins are saturated by high-physiological concentrations of cortisol, considerable variations of free plasma cortisol concentrations occur during diurnal changes (1-100 nmol/l) [21] . In contrast, cortisone, the main 11-oxo steroid in human plasma, circulates at about 50 to 100 nmol/l, does not have a pronounced diurnal variation and is barely protein-bound resulting in continuously higher "free" plasma concentrations compared to cortisol [22] . Thus, plasma cortisone can be regarded as an inactive glucocorticoid storage pool that is constantly provided to 11β-HSD1 reductase to maintain local active glucocorticoid concentrations even in periods of low plasma cortisol concentrations, e.g. during the diurnal nadir. By expression of 11β-HSD1, the target tissue itself is equipped to regulate its own glucocorticoid concentration and subsequently its glucocorticoid responsiveness on the prereceptor level by adjusting the rate of local glucocorticoid activation [23] . This is of particular interest in metabolically active tissues where glucocorticoids functionally oppose insulin action.
Regulation of 11β-HSD1 expression. Though cortisol is the product of 11β-HSD1 action, it also stimulates 11β-HSD1 expression in hepatocytes, adipocytes and myoblasts [24, 25] . Cortisol induces adipogenesis and 11β-HSD1 activity in preadipocytes whereby 11β-HSD1 could well contribute to adipocyte differentiation by converting cortisone to cortisol [25, 26] . Induction of 11β-HSD1 by 11-dehydro glucocorticoids such as cortisone provides a positive feedback loop [27] that is attenuated by down-regulation of the ligand-binding and transactivating glucocorticoid receptor (GR) α [28] and stimulated by parallel expression of GRβ, a dominant negative regulator of GRα [29] .
Insulin seems to down-regulate 11β-HSD1 activity but data are not unequivocal at this point. In human adipose stromal cells (i.e. preadipocytes) insulin attenuates 11β-HSD1 activity and similar results were found in fibroblasts, hepatoma cells, and myoblasts, depending on culture conditions [30, 31] . However, insulin synergises with glucocorticoids to stimulate adipocyte differentiation that is associated with the induction of 11β-HSD1 activity [25] .
In addition, other hormones and cytokines are able to regulate 11β-HSD1 activity. Growth hormone/IGF-1 reduces 11β-HSD1 activity [32] , whereas TNFα, IL-1β and IL-6 increase 11β-HSD1 expression at least in adipose stromal cells [33] . Up-regulation by TNFα is particularly interesting in that TNFα seems to reduce insulin sensitivity in adipose tissue. Since insulin itself counteracts the stimulatory effect of TNFα [34], a vicious circle could be postulated with lower insulin sensitivity being less able to abolish TNF-driven 11β-HSD1 up-regulation. Thereby, stimulation of 11β-HSD1 activity by TNFα could be a means for a selfpotentiating negative effect on insulin sensitivity. Notably, also estrogens can suppress 11β-HSD1 expression possibly contributing to their metabolic and cardiovascular effects in premenopausal women [35] .
Only scarce data are available on regulation of expression of the HSD11B1 gene (encoding 11β-HSD1) at the molecular level although the rat promoter has been cloned years ago [36] . At least in rat liver cells, CCAAT/enhancer binding protein (C/EBP) α is an important factor for HSD11B1 transcription [37] . In murine adipocytes, typical transcription factors associated with adipocyte differentiation, such as peroxisome proliferator-activated receptor (PPAR) γ and liver X receptors (LXR) repress 11β-HSD1 expression by unknown molecular mechanisms [38] . Differential expression of 11β-HSD1 in omental compared to subcutaneous preadipocytes and adipocytes could be due to differences in transcription factor and cofactor binding but molecular data are still lacking.
11β-HSD1 in adipocyte biology
Switch in 11β-HSD1 expression during adipogenesis. 11β-HSD1 but not 11β-HSD2 is expressed in human preadipocytes but there are considerable site-specific Interconversion of cortisone and cortisol as catalysed by 11β-HSD type 1 and 2. 11β-HSD1 usually acts as oxo-reductase but can also catalyse the 11β-dehydrogenase reaction as discussed in the text differences depending on whether preadipocytes were isolated from visceral or subcutaneous fat depots [7] . Preadipocytes from visceral adipose tissue express markedly more 11β-HSD1 mRNA and oxo-reductase activity than subcutaneous adipose stromal cells when preadipocytes were cultured for more than 10 days [7] . Taking a closer view on freshly isolated human preadipocytes from omental origin, 11β-HSD1 appears to predominantly catalyse the 11β-dehydrogenase reaction thereby inactivating cortisol to cortisone, whereas the glucocorticoid-activating oxo-reductase reaction predominates during adipocyte differentiation only of omental but not of subcutaneous adipose stromal cells [39] . Notably, 11β-HSD1 mRNA changes only minimally during differentiation of human adipose stromal cells [39] in contrast to murine preadipocyte cell lines that do not express 11β-HSD1 until terminally differentiated into adipocytes [40] . However, data showing 11β-dehydrogenase activity have to be taken with caution since 11β-dehydrogenase activity of 11β-HSD1 is characteristic for the isolated enzyme located outside intact cells and is hence generally regarded as an indicator of cellular destruction. Nevertheless, a switch from 11β-dehydrogenase to oxo-reductase activity of 11β-HSD1 could be caused by altered redox potentials due to changes in microsomal NADPH:NADP + ratio [39] . The switch from dehydrogenase to oxo-reductase activity during human preadipocyte differentiation is accompanied by up-regulation of hexose-6-phosphate dehydrogenase (H6PDH) [41] . H6PDH can catalyse the first to steps of the pentose phosphate pathway to generate NADPH thereby regulating the microsomal redox potential. The critical role of H6PDH for 11β-HSD1 oxoreductase activity is underlined by the fact that H6PD mutations together with HSD11B1 mutations are associated with human cortisone reductase deficiency [41] .
If a change from 11β-dehydrogenase to oxo-reductase activity occurs during adipogenesis in visceral adipose tissue, the set point of the switch could have a considerable effect on the development of visceral obesity (Fig. 2) [39]. Adipose tissue hypertrophy depends on proliferation of preadipocytes, their differentiation to adipocytes and increase in adipocyte size by lipid accumulation. Cortisol adds to that process in that it inhibits cellular proliferation but strongly promotes adipocyte differentiation [26, 42] . Hence, cortisol-inactivating 11β-dehydrogenase activity of 11β-HSD1 in preadipocytes could facilitate their proliferation and protect themselves from differentiation to adipocytes in an autocrine fashion. Generation of cortisol by a switch to oxo-reductase activity during early differentiation of visceral adipocytes then promotes terminal adipogenesis. Since GRα expression is markedly higher in visceral compared to subcutaneous adipose tissue [43] , the differentiating effect of glucocorticoids is supposed to be more pronounced in visceral . These findings reveal an impaired intracellular activation of glucocorticoids in 11β-HSD1 −/− mice that antagonises insulin action under physiological conditions. To analyse the effect of increased expression of 11β-HSD1 in adipose tissue as it occurs in obesity, transgenic mice were generated with the 11β-HSD1 gene driven by the adipocyte-specific fatty acid binding protein (aP2) promoter [43] . Transgenic mice showed visceral obesity with predominant hypertrophy of the mesenterial fat depots that exhibit higher GRα expression. Notably, the transgene was expressed only two to threefold more pronounced than in the control animals and hence corresponded well to 11β-HSD1 expression in other models of obesity. Corticosterone concentrations in adipose tissues and the portal vein were increased in such transgenic animals compared to non-transgenic control animals, whereas circulating corticosterone concentrations remained unaltered. Notably, overexpression of 11β-HSD1 solely in adipose tissue resulted in whole body insulin resistance exemplified by an abnormal plasma glucose response to i.v. glucose injection, diminished reduction plasma glucose by insulin and increase plasma NEFA. However, the aP2 promoter is activated only in adipocytes but not in preadipocytes. Hence, adipose tissue hypertrophy in 11β-HSD1 transgenic animals was due to increased adipocyte size only, whereas adipose tissue hypertrophy in obesity is due to a combination of increased adipocyte size and preadipocyte hyperplasia. Thus, this elegant paper [43] elucidated the effect of 11β-HSD1 in adipocytes but the consequences of 11β-HSD1 overexpression in preadipocytes for the development of visceral obesity remain obscure.
Dysregulation of 11β-HSD1 in human obesity
Obesity seems to be associated with increased cortisol excretion [48] that correlates with BMI [49]. However, plasma cortisol concentration is not increased in obese subjects but is usually lower than in non-obese subjects, a finding that could relate to enhanced peripheral metabolism of cortisol in obesity. Increased plasma ACTH concentrations point to an increased hypothalamo-pituitary-adrenal (HPA) axis activity in obese subjects that could be due to a relative insensitivity to glucocorticoid feedback [50, 51] but alterations in HPA axis regulation in obesity are complex and cannot be discussed here in detail. Notably, 11β-HSD1 expression is also implicated in the central nervous system including local glucocorticoid production in key control sites for the HPA axis as shown by exaggerated plasma glucocorticoid responses to stress in 11β-HSD1 −/− mice [46] (Fig. 3) .
An indication for a pathophysiological role of 11β-HSD1 in the generation of visceral adipose tissue in obesity could be derived from the description of a patient with biochemically proven Cushing's syndrome and concomitantly impaired cortisone to cortisol conversion who lacked the classical clinical phenotype including central obesity [52] . However, a defective 11β-HSD1 oxo-reductase activity does not necessarily have to cause a lean phenotype [53] . 3 . Implication of 11β-HSDs for glucocorticoid feedback regulation within the hypothalamic-pituitary-adrenal axis. Cortisol synthesis in the adrenals is regulated by the hypothalamic-pituitary-adrenal axis. Cortisol is also generated from cortisone in 11β-HSD1-expressing peripheral tissues, e.g., liver and adipose tissue. In addition to circulating cortisol levels, 11β-HSD1 expression in brain regulates the local availability of cortisol to bind to the glucocorticoid receptor (GR) in hypothalamus and the pituitary gland for negative feedback regulation (broken line). ACTH, adrenocorticotropic hormone; CRH, corticotropin-releasing hormone; GR, glucocorticoid receptor
According to a number of previous studies, obesity is associated with tissue-specific dysregulation of 11β-HSD1 activity in humans [23] . Whereas whole body 11β-HSD1 activity (mainly reflecting hepatic expression) is down-regulated particularly in visceral obesity, activity in adipose tissue is increased in obese subjects [54] . These human studies have been confirmed by data from leptin-resistant obese Zucker rats [55] . Only subcutaneous adipose tissue could be investigated in human studies but not the metabolically important adipose tissue from visceral sites. Moreover, urinary metabolite ratios as used in some studies should be taken with caution as an indicator for 11β-HSD activity and do not correlate with BMI but only with the ratio of visceral to subcutaneous fat, e.g. as measured by computerised tomography [56] . Genetic analyses of microsatellite markers within the 11β-HSD1 gene showed associations with cortisol metabolite ratios and WHR indicating a possible contribution of 11β-HSD1 to the development particularly of visceral obesity. These data point to the necessity to evaluate the type of obesity when studying the pathophysiological role of 11β-HSD1 in adipose tissue.
Since 11β-HSD1 expression and activity differs in preadipocytes versus mature adipocytes, analysis of adipose tissue as a whole does not provide sufficient insight on its pathophysiological role. In situ hybridisation on adipose tissue of obese patients compared to lean control subjects showed increased 11β-HSD1 mRNA expression in the adipocyte compartment of subcutaneous adipose tissue and in the visceral fat in both adipocytes and stroma [57] . These data confirm previous in vitro data from isolated preadipocytes and emphasise site-specific alterations of 11β-HSD1 expression particularly in preadipocytes.
The tissue-specific dysregulation of 11β-HSD1 was seemingly contradicted by recent data analysing preadipocytes and adipocytes from visceral and subcutaneous adipose tissue samples derived from non-obese and obese patients [58] . 11β-HSD1 mRNA expression and activity in preadipocytes from visceral origin was considerably lower exclusively in visceral preadipocytes from obese compared to non-obese subjects when cultured with cortisol, whereas no differences concerning tissue location and BMI were found when evaluating mature adipocytes. Moreover, 11β-HSD1 mRNA expression evaluated by real-time RT-PCR in whole adipose tissue from omental and subcutaneous origin was unaltered in obese compared with lean subjects. Though these data could be taken as an argument against a pathophysiological role of 11β-HSD1 in obesity they have to be interpreted with caution since the type of obesity (android or gynoid) remained undefined in the female population under study. Moreover, we do not have data on glucocorticoid sensitivity of preadipocytes and adipocytes in visceral and subcutaneous adipose tissue from obese versus lean subjects. A clue for explaining the pathophysiological importance of these data could lie in the nature of adipose tissue hypertrophy and a switch in the 11β-HSD1 reaction from 11β-dehydrogenase to oxo-reductase in visceral preadiocytes as discussed above (Fig. 2) . Adipose tissue hypertrophy results not only from increased adipocyte size but also from an increased number of adipocytes that require proliferation of preadipocytes. Since cortisol inhibits omental preadipocyte proliferation, decreased 11β-HSD1 mRNA levels and oxo-reductase activity in omental preadipocytes could result in enhanced proliferation and hence promote visceral adipose-tissue mass in obese patients. Preadipocytes cultured in the presence of cortisol start adipocyte differentiation that is associated with an increase of 11β-HSD1 oxo-reductase activity. Hence, the blunted increase of 11β-HSD1 activity in cultured visceral preadipocytes from obese patients could indicate a higher threshold for the switch to oxo-reductase reaction during adipogenesis, leading to adipose tissue hypertrophy.
In conclusion, most available data show increased 11β-HSD1 expression and activity in visceral adipose tissue, at least in preadipocytes and possibly also in adipocytes, in obese patients compared to lean control subjects. However, patients with visceral obesity still have to be evaluated with methods reliably reflecting 11β-HSD1 expression in vivo.
11β-HSD1 and insulin resistance
A number of cross-sectional studies have indicated that increased serum cortisol concentrations or 24-h urinary cortisol excretion is correlated with clinical manifestations of the metabolic syndrome (e.g. [59, 60, 61] ) and might explain the association of low birth weight and insulin resistance [62] . Alterations in cortisol excretion and HPA axis regulation have specifically been observed in diabetes mellitus [63, 64, 65, 66, 67] . A recent study involving moderately overweight Type 2 diabetic patients and control subjects matched for weight, height, BMI and blood pressure showed increased central and peripheral sensitivity to glucocorticoids in diabetic patients even if their metabolism was optimally controlled (HbA 1c 6.9±0.2% vs 6.0±0.1%) [68] . Overall generation of cortisol from cortisone (reflecting mainly hepatic 11β-HSD1 activity) was impaired in diabetic patients but there were no differences in 11β-HSD1 activity in subcutaneous fat biopsies. On the other hand, increased sensitivity to glucocorticoid action in the presence of unaltered glucocorticoid secretion in diabetic patients indicates an imbalance leading to inappropriately high glucocorticoid responses. Since the patients and control subjects were matched for weight in that study [68] , changes in glucocorticoid activation and sensitivity in diabetes patients are beyond the dysregulation found in simple primary obesity. Thus, abnormalities in adipose tissue cortisol metabolism and/or glucocorticoid sensitivity could contribute to insulin resistance and thereby to the development of Type 2 diabetes and other manifestations of the metabolic syndrome.
In addition to 11β-HSD1 expression in adipose tissue, expression of glucocorticoid receptor (GRα) and 11β-HSD1 in myoblasts is positively correlated with characteristics of the metabolic syndrome, namely insulin resistance, BMI and blood pressure [69] . Hence dysregulation of 11β-HSD1 in muscle, the major target tissue of insulin action seems to parallel its regulation in adipose tissue in obesity and the metabolic syndrome.
Type 2 diabetes is characterised by disturbed insulin secretion in addition to decreased insulin sensitivity [70, 71] . In contrast to the well-known secondary hyperinsulinaemia in response to acute cortisol exposure in healthy subjects [72] , glucocorticoids even in physiological concentrations directly inhibit insulin secretion from pancreatic islets in vitro and in vivo [10, 73, 74, 75, 76] . 11β-HSD1 is expressed in islet cells and 11-oxo glucocorticoids activated by 11β-HSD1 diminish insulin secretion [76] . Hence, 11β-HSD1 could interfere not only with peripheral insulin sensitivity but also with insulin secretion. Consequently, 11β-HSD1 could be implicated not only in the development of visceral obesity but also in the deterioration of insulin sensitivity and in the dysregulation of insulin secretion resulting in Type 2 diabetes mellitus.
Studies with 11β-HSD inhibitors.
Pharmacological studies showed that inhibition of 11β-HSD1 exerts a positive effect on insulin sensitivity in diabetic subjects. This also applies to healthy subjects exposed to an unspecific 11β-HSD inhibitor that blocks 11β-HSD Type 1 and Type 2 as shown by euglycaemic, hyperinsulinaemic clamp studies [77] . In a recent doubleblind crossover study with the unspecific 11β-HSD inhibitor carbenoxolone, diet-controlled non-obese diabetic patients (HbA 1c <8%) and matched control subjects were evaluated by euglycaemic hyperinsulinaemic clamps with or without concomitant hyperglucagonaemia [78] . Unspecific inhibition of 11β-HSDs in Type 2 diabetic patients did not affect the glucose disposal rate or suppression of NEFA during hyperinsulinaemia, but reduced glycogenolysis and associated glucose production rate during hyperglucagonaemia. Though an effect on gluconeogenesis could not be shown, this study showed that even in nonobese patients with only little visceral adipose tissue, inhibition of 11β-HSD1 could exert beneficial effects on glucose homeostasis. Since most Type 2 diabetic patients are obese with predominant hypertrophy of visceral adipose tissue that highly expresses 11β-HSD1, inhibition or down-regulation of 11β-HSD1 could improve glycaemia.
In contrast to the use of unspecific 11β-HSD inhibitors causing hypertension and hypokalaemia by inhibition of renal 11β-HSD2, a selective inhibitor of murine 11β-HSD1 (BVT.2733) has been shown in spontaneously hyperglycaemic KKA y mice to lower hepatic PEPCK and glucose-6-phosphatase mRNA expression as well as blood glucose and serum insulin concentrations [79] . Selective inhibitors of human 11β-HSD1 have already been synthesised [80] . These drugs could lower intrahepatic and intra-adipose tissue cortisol concentrations and thereby regionally enhance insulin sensitivity, reduce gluconeogenesis and potentially even adiposity. Though available metabolic data are still restricted to rodents they are highly promising for clinical studies to come in the near future.
Studies with selective 11β-HSD1 inhibitors will prove or disprove the concept of 11β-HSD1 contributing to the development of visceral obesity and Type 2 diabetes. However, if successful in their application, specific 11β-HSD1 inhibitors could be particularly beneficial for obese patients with insulin resistance syndrome and Type 2 diabetes. Since 11β-HSD1 expression is dysregulated in these disorders in a tissuespecific manner with high expression in adipose tissue but low activity in liver, clinical effects of selective 11β-HSD1 inhibitors could vary with their local concentration in adipose tissue and liver.
In addition to effects in metabolically active tissues, 11β-HSD1-induced changes in the HPA axis have to be awaited since inhibition of central nervous system 11β-HSD1 could disrupt negative HPA feedback regulation [46] (Fig. 3) . 11β-HSD1 is important for glucocorticoid activation also in the brain and regulates the HPA axis. Thus, inhibition of hypothalamic 11β-HSD1 could blunt negative feedback regulation by reducing local cortisol concentration and result in increased secretion of glucocorticoids from the adrenals. To avoid this hypothalamic interference by specific 11β-HSD1 inhibitors such drugs should be unable to cross the blood brain barrier. On the other hand, 11β-HSD1 inhibition in the central nervous system could protect the brain from the adverse effects of GCs that are proposed to occur during aging [81] . Thus 11β-HSD1 inhibitors have the potential of becoming an interesting novel class of drugs in the future even beyond the treatment of obesity and Type 2 diabetes.
Down-regulation of 11β-HSD1 expression.
Besides pharmacological inhibition of 11β-HSD1 enzymatic activity, also down-regulation of the expression of the HSD11B1 gene could reduce local glucocorticoid activation. Several nuclear receptors have been shown to down-regulate 11β-HSD1 expression in adipocytes and/or liver through unknown molecular mechanisms. This applies to PPARs, which play important roles in metabolic regulation and adipocyte differentiation. PPARγ is mainly expressed in adipose tissue and its agonists, the thiazolidinediones, which are clinically applied to lower insulin resistance in Type 2 diabetic patients by widely unknown mechanisms [82, 83] . PPARγ agonists down-regulate 11β-HSD1 expression in adipose tissue and thereby decrease whole body cortisone to cortisol conversion in diabetic mice [38] . Thus, PPARγ agonists could mediate at least part of their beneficial effect on insulin sensitivity by downregulation of 11β-HSD1. Also agonists of PPARα mainly expressed in liver, down-regulate 11β-HSD1 expression and activity in livers of wild-type but not of PPARα −/− mice [84] . However, PPARα agonists do not have a relevant effect on insulin sensitivity in diabetic patients perhaps because hepatic 11β-HSD1 expression appears already down-regulated in visceral obesity [23] .
Very recently, treatment with a liver X receptor agonist was shown to down-regulate both 11β-HSD1 expression and activity in adipocytes and livers in wildtype but not in LXRα −/− β −/− mice in parallel with reduced PEPCK expression [85] . Moreover, LXR agonist treatment also decreased blood glucose concentrations in diabetic mice [86] though mechanisms other than down-regulation of 11β-HSD1 could be responsible for that phenomenon [87, 88] . Nevertheless, both LXR as well as PPARγ agonists could mediate their anti-diabetic action at least in part via down-regulation of 11β-HSD1. Although very promising, all data so far have been derived from mouse studies and it remains to be seen whether PPARγ and LXR agonists also repress 11β-HSD1 expression in humans.
Conclusions
Currently available data particularly in genetically altered mice suggest 11β-HSD1 to have a pathophysiological role in the development of obesity and in the insulin-resistance syndromes including Type 2 diabetes mellitus. Published data are derived from rodent model systems but not from studies on humans which are urgently needed to define the pharmacological potential of specific inhibitors of 11β-HSD1 for the treatment of visceral obesity and the metabolic syndrome. The situation has recently changed by introduction of specific 11β-HSD1 inhibitors with selectivity for mice and humans, respectively [80] . A specific inhibitor for murine 11β-HSD1 has been successfully applied in diabetic mice. Clinical studies with these potential drugs are needed to decide on the concept of the 11β-HSD1 blockade as a novel mode of treatment for patients with obesity or Type 2 diabetes.
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